Cargando…

Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics

Signaling of the receptor tyrosine kinase Axl and its ligand Gas6 is crucially involved in the development of liver fibrosis and hepatocellular carcinoma (HCC) by activation of hepatic stellate cells and modulation of hepatocyte differentiation. Shedding of Axl’s ectodomain leads to the release of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holstein, Elisa, Binder, Mathias, Mikulits, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321118/ https://www.ncbi.nlm.nih.gov/pubmed/30567378 http://dx.doi.org/10.3390/ijms19124111

Ejemplares similares

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

Transforming Growth Factor‐β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma
por: Haider, Christine, et al.
Publicado: (2018)

PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma
por: Hedrich, Viola, et al.
Publicado: (2023)

Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
por: Hedrich, Viola, et al.
Publicado: (2021)

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis
por: Dengler, Mirko, et al.
Publicado: (2017)

Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review)
por: Reichl, Patrick, et al.
Publicado: (2016)

Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression
por: He, Lirui, et al.
Publicado: (2020)

Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma
por: Xu, Mengjiao, et al.
Publicado: (2022)

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
por: von Mässenhausen, Anne, et al.
Publicado: (2016)

Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma
por: Liu, Jian, et al.
Publicado: (2016)

Circular RNAs Sparkle in the Diagnosis and Theranostics of Hepatocellular Carcinoma
por: Wang, Menglan, et al.
Publicado: (2021)

Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic
por: Liu, Yunxi, et al.
Publicado: (2021)

Immunological Aspects of AXL/GAS‐6 in the Context of Human Liver Regeneration
por: Ortmayr, Gregor, et al.
Publicado: (2021)

The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis
por: Staufer, Katharina, et al.
Publicado: (2017)

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2019)

AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
por: Chai, Zong-Tao, et al.
Publicado: (2021)

Proteolytic Shedding of Human Colony‐Stimulating Factor 1 Receptor and its implication
por: Wei, Yue, et al.
Publicado: (2021)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

The Receptor Tyrosine Kinase AXL in Cancer Progression
por: Rankin, Erinn B., et al.
Publicado: (2016)

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
por: Myers, Kayla V., et al.
Publicado: (2019)

Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting
por: Bonferoni, Maria Cristina, et al.
Publicado: (2020)

Gadolinium-Based Nanoparticles for Theranostic MRI-Guided Radiosensitization in Hepatocellular Carcinoma
por: Hu, Pengcheng, et al.
Publicado: (2019)

Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma
por: Vaughan, Hannah J., et al.
Publicado: (2022)

Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells
por: Wittmann, Philipp, et al.
Publicado: (2015)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Snail mediates crosstalk between TGFβ and LXRα in hepatocellular carcinoma
por: Bellomo, Claudia, et al.
Publicado: (2017)

Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
por: Gustafsson, Anna, et al.
Publicado: (2009)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation
por: Morén, Anita, et al.
Publicado: (2019)

Comprehensive analysis of the novel omicron receptor AXL in cancers
por: Zhang, Wei-Na, et al.
Publicado: (2022)

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)

Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma—An Overview
por: D’Agnano, Igea, et al.
Publicado: (2020)

Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma
por: Wang, Yang, et al.
Publicado: (2022)

Curcumin and Its Derivatives as Theranostic Agents in Alzheimer’s Disease: The Implication of Nanotechnology
por: Shabbir, Umair, et al.
Publicado: (2020)

Transforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells
por: Koudelkova, Petra, et al.
Publicado: (2017)

Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
por: Scherschinski, Lea, et al.
Publicado: (2022)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour
por: Wei, Mingze, et al.
Publicado: (2022)

Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection
por: Song, Xiaoting, et al.
Publicado: (2020)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fago87muh4qvmeh12gughhint4